Sanofi inks ma­jor AI deal to im­prove clin­i­cal de­vel­op­ment odds with $270M cash in­vest­ment

For most of the up-and-com­ing AI play­ers in the biotech space, we’ve seen a slew of deals to uti­lize AI and ma­chine learn­ing in drug dis­cov­ery and man­u­fac­tur­ing. Com­pa­nies such as In­sil­i­co and Gen­er­ate — just to name two — have been bag­ging part­ner­ships and deals left and right.

Sanofi, though, has now lined up a new deal with one of the low­er pro­file ops in Eu­rope, go­ing with a big in­vest­ment with an eye to im­prov­ing its odds in clin­i­cal de­vel­op­ment — and the biotech in­dus­try’s newest AI deal touts a new in­gre­di­ent: fed­er­at­ed learn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER